Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $3.02 in the prior trading day, Cardiff Oncology Inc (NASDAQ: CRDF) closed at $1.22M, up 1495783%. In other words, the price has increased by $1495783 from its previous closing price. On the day, 1.5 million shares were traded. CRDF stock price reached its highest trading level at $3.2 during the session, while it also had its lowest trading level at $2.96.
Ratios:
Our goal is to gain a better understanding of CRDF by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.22 and its Current Ratio is at 6.22. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on September 06, 2024, initiated with a Buy rating and assigned the stock a target price of $8.
On December 08, 2021, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $19.Robert W. Baird initiated its Outperform rating on December 08, 2021, with a $19 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 17 ’24 when Levine James E. bought 2,752 shares for $5.42 per share. The transaction valued at 14,905 led to the insider holds 65,316 shares of the business.
Levine James E. bought 2,400 shares of CRDF for $12,000 on Dec 18 ’24. The Chief Financial Officer now owns 67,716 shares after completing the transaction at $5.00 per share. On Dec 16 ’24, another insider, Levine James E., who serves as the Chief Financial Officer of the company, bought 2,564 shares for $3.83 each. As a result, the insider paid 9,820 and bolstered with 62,564 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRDF now has a Market Capitalization of 206230288 and an Enterprise Value of 127699144. For the stock, the TTM Price-to-Sale (P/S) ratio is 349.54 while its Price-to-Book (P/B) ratio in mrq is 2.91. Its current Enterprise Value per Revenue stands at 217.545 whereas that against EBITDA is -2.47.
Stock Price History:
The Beta on a monthly basis for CRDF is 1.57, which has changed by 0.3135593 over the last 52 weeks, in comparison to a change of 0.09544468 over the same period for the S&P500. Over the past 52 weeks, CRDF has reached a high of $5.64, while it has fallen to a 52-week low of $2.01. The 50-Day Moving Average of the stock is 1.13%, while the 200-Day Moving Average is calculated to be -5.66%.
Shares Statistics:
The stock has traded on average 1.22M shares per day over the past 3-months and 1482100 shares per day over the last 10 days, according to various share statistics. A total of 66.53M shares are outstanding, with a floating share count of 60.75M. Insiders hold about 8.68% of the company’s shares, while institutions hold 42.24% stake in the company. Shares short for CRDF as of 1748563200 were 17633640 with a Short Ratio of 14.47, compared to 1745971200 on 17475197. Therefore, it implies a Short% of Shares Outstanding of 17633640 and a Short% of Float of 27.22.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
